MGMT and glioblastoma: Our analysis reveals that it is important to include MGMT status to identify the impact of EGFRvIII on therapy outcome: MGMT-M/EGFRvIII+ GBM patients showed the most favorable survival after standard of care treatment (Fig. 1d, e).